Loading
A phase 2/3 trial of encorafenib and cetuximab in colorectal cancer, run by Alliance for Clinical Trials in Oncology, active but no longer recruiting.
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer is a phase 2/3, randomised interventional study registered as NCT05710406 by Alliance for Clinical Trials in Oncology, with a registry enrolment figure of 1 participants, started 2023-08-16 and due to reach its primary completion in 2034-06-01. Interventions recorded: Encorafenib; Cetuximab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Patient Observation. Conditions listed: Colon Adenocarcinoma; Microsatellite Stable Colon Carcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8; Stage III Colon Cancer AJCC v8. Primary outcome: Circulating tumor deoxyribonucleic acid (ctDNA) clearance rate (Phase II; ctDNA positive cohort); tDNA recurrence-free survival rate (ctDNA-RFS) (Phase II; ctDNA negative cohort); Disease free survival (DFS) (Phase III). Colorectal eligibility wording from the registry: "* Pre-registration for central tumor testing will occur after colon resection". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Encorafenib, Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Encorafenib, BRAF V600E-mutant colorectal cancer, Colorectal cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag colorectal-deep-dive.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.